|AVEXIS, INC. filed this Form S-1/A on 02/01/2016|
Table of Contents
of Mr. Carbona's stock option awards, as computed in accordance with ASC 718 as of the modification date on April 22, 2015, that were accelerated in connection with the
termination of Mr. Carbona's employment, to which each of Mr. Harkey and Dr. Genecov had the right to purchase under the terms of the Stock Purchase and Option Agreement described
in "Executive CompensationEquity-Based AwardsStock Purchase and Option Agreement" below. See "Executive CompensationPayments upon Termination or Change in
Control" below for a discussion of the acceleration of the 53,820 unvested stock options held by Mr. Carbona at the time of the termination of his employment. We determined that the
acceleration of vesting was a Type III modification pursuant to ASC 718. Therefore, we recognized the amount immediately since the awards did not require further service.
of December 31, 2015, the number of unvested stock awards held by Dr. Kaspar was 1,750,794. Dr. Kaspar did not have any outstanding
option awards as of December 31, 2015.
amount represents cash consulting fees paid to Dr. Kaspar pursuant to his consulting agreement.
- Mr. Koh
joined the board in June 2015.
- Mr. Verwiel
joined the board in December 2015.
© AveXis, Inc. All Rights Reserved.